Glucagon-Like Peptide-1 Receptor–Targeted PET/CT With 68Ga-HBED-CC-Exendin-4 in Localizing Insulinoma
68 Ga-HBED-CC-exendin-4 is an effective agent for localizing insulinoma showing similar detectability and tumor-to-background ratio compared with 68 Ga-NOTA-exendin-4. Notably, 68 Ga-HBED-CC-exendin-4 exhibits significantly lower renal uptake than 68 Ga-NOTA-exendin-4, which might potentially benefit the detection of the tumors adjacent to the left kidneys.
Authors
- Jiarou Wang
- Jingci Chen (ORCID: https://orcid.org/0000-0002-2349-3309)
- Qingqing Pan (ORCID: https://orcid.org/0000-0003-2815-0767)
- Haiyan Hong (ORCID: https://orcid.org/0000-0003-2826-0464)
- Guochang Wang (ORCID: https://orcid.org/0000-0001-8246-2441)
- Yaping Luo (ORCID: https://orcid.org/0000-0002-5787-1136)
- Linlin Li (ORCID: https://orcid.org/0000-0001-9180-6357)
- Lin Zhu (ORCID: https://orcid.org/0000-0001-9530-8531)
- Wenbin Jin (ORCID: https://orcid.org/0000-0001-7859-2972)
- Rongxi Wang (ORCID: https://orcid.org/0000-0002-2448-2441)
- Zhaohui Zhu (ORCID: https://orcid.org/0000-0002-3146-6714)
- Hank F. Kung
- Heng Ma (ORCID: https://orcid.org/0000-0001-5914-5675)
Institutions
- Fujian Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Normal University (CN)
- Peking Union Medical College Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1097/rlu.0000000000005533
- Citations
- 9
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 3.48